Cartesian Therapeutics (RNAC) Free Cash Flow (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Free Cash Flow of -$22.2 million for Q1 2026, up 6.13% year-over-year from -$20.9 million in Q1 2025, and down 21.92% quarter-over-quarter from -$18.2 million in Q4 2025.
Cartesian Therapeutics (RNAC) Free Cash Flow (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Free Cash Flow data on file, last reported at -$22.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$22.2 million, up 6.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.9 million (down 92.49% YoY), and the FY2025 annual result was -$79.4 million, down 142.3% from the prior year.
- Free Cash Flow declined to -$22.2 million in Q1 2026 per RNAC's latest filing, from -$18.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $7.5 million in Q3 2024 and troughed at -$23.6 million in Q1 2025.
- A 5-year average of -$12.9 million and a median of -$12.7 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 181.99% in 2024, then sank 365.27% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$12.1 million in 2022, then tumbled by 93.61% to -$23.3 million in 2023, then jumped by 66.99% to -$7.7 million in 2024, then tumbled by 136.2% to -$18.2 million in 2025, then decreased by 21.92% to -$22.2 million in 2026.
- Business Quant data shows RNAC's Free Cash Flow at -$22.2 million in Q1 2026, -$18.2 million in Q4 2025, and -$19.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -22.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.19 Mn |
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -18.20 Mn |
| Dec 31, 2025 | -18.20 Mn |
| Sep 30, 2025 | -19.87 Mn |
| Sep 30, 2025 | -19.87 Mn |
| Jun 30, 2025 | -17.67 Mn |
| Jun 30, 2025 | -17.67 Mn |
| Mar 31, 2025 | -23.64 Mn |
| Mar 31, 2025 | -23.64 Mn |
| Dec 31, 2024 | -7.71 Mn |
| Dec 31, 2024 | -7.71 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Jun 30, 2024 | -16.64 Mn |
| Jun 30, 2024 | -16.64 Mn |
| Mar 31, 2024 | -15.92 Mn |
| Mar 31, 2024 | -15.92 Mn |
| Dec 31, 2023 | -23.35 Mn |
| Dec 31, 2023 | -23.35 Mn |